Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).
S. M. Horwitz
Consultant or Advisory Role - Celgene
Stock Ownership - Celgene
Honoraria - Celgene
B. Coiffier
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
F. M. Foss
Consultant or Advisory Role - Celgene; Eisai
Honoraria - Allos Therapeutics; Cephalon; Eisai; Merck
H. M. Prince
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
L. Sokol
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Gloucester Pharmaceuticals
M. Greenwood
No relevant relationships to disclose
D. Caballero
No relevant relationships to disclose
P. Borchmann
No relevant relationships to disclose
F. Morschhauser
Honoraria - Celgene
M. Wilhelm
No relevant relationships to disclose
L. C. Pinter-Brown
No relevant relationships to disclose
S. Padmanabhan
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
A. R. Shustov
Honoraria - Celgene
Research Funding - Gloucester Pharmaceuticals
J. Nichols
Employment or Leadership Position - Celgene
J. Balser
No relevant relationships to disclose
S. Carroll
Employment or Leadership Position - Celgene
B. Pro
Research Funding - Celgene